Apogee Therapeutics

APGEPhase 2

Founded 2022apogeetherapeutics.com

Founded in 2022, Apogee Therapeutics aims to reshape the standard of care for inflammatory and immune diseases by developing potentially best-in-class biologics with optimized dosing intervals. Its pipeline includes monotherapies and rational combinations targeting validated pathways like IL-13, OX40L, and TSLP across dermatological, respiratory, and gastroenterological conditions. The company is publicly traded (NASDAQ: APGE) and is advancing multiple programs with key clinical readouts expected in 2026.

Market Cap

$3.7B

Founded

2022

APGE · Stock Price

USD 66.04+44.81 (+211.07%)

Historical price data

AI Company Overview

Technology Platform

Proprietary antibody engineering platform focused on enhancing FcRn binding to extend circulatory half-life, enabling subcutaneous therapies with significantly less frequent dosing (e.g., every 3-6 months).

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
APG777 + APG777 + APG777	Atopic Dermatitis	Phase 2
APG777 + Placebo	Atopic Dermatitis	Phase 2
APG777 + APG990 + Dupilumab	Atopic Dermatitis	Phase 1
APG777 + Placebo	Asthma	Phase 1

Funding History

Total raised: $749M

IPO$300MUndisclosedJul 28, 2023

Series B$300MRA Capital ManagementJun 15, 2023

Series A$149MFairmount Funds ManagementJun 15, 2022

Opportunities

Significant growth opportunity lies in expanding zumilokibart into multiple large I&I indications (asthma, EoE, chronic rhinosinusitis with nasal polyps, etc.) and developing first-in-class combinations (APG279, APG273) that could address broader inflammatory pathways.

Successfully demonstrating a best-in-class dosing interval could drive rapid market penetration in crowded therapeutic areas.

Risk Factors

Key risks include clinical trial failures, intense competition from established biologics like Dupixent, the challenge of commercializing in a crowded market, and dependence on raising substantial capital to fund late-stage development as a pre-revenue company.

Competitive Landscape

Competes directly with major pharma companies like Sanofi/Regeneron (Dupixent), Eli Lilly (Lebrikizumab), and AstraZeneca (Tezspire). Apogee's primary differentiation is its half-life extension technology aiming for less frequent dosing, and its strategy of targeting multiple inflammatory pathways through novel combinations.

Publications

Pipeline